Sharon Hodgson MP: speeches 2026

Speeches

• 14 Apr 2026 · Healthy Babies Funding · Hansard source

  More

  Despite the huge success of Sure Start, which my hon. Friend details, the Tory-Lib Dem Government disastrously cut Sure Start centres, leaving parents and babies without any support. That is why this Government are investing £200 million as part of an almost £1 billion package for Best Start family hubs and Healthy Babies. This funding will help all areas to integrate neighbourhood-based health services in hubs, and it will roll out to his area during the next decade.

• 14 Apr 2026 · Healthy Babies Funding · Hansard source

  More

  I thank the hon. Lady for her good wishes. She may be aware that on 19 January, the Secretary of State met Jesy Nelson and Giles Lomax, the CEO of the charity SMA UK, to discuss the very issue of newborn screening for SMA. The NHS is planning an in-service evaluation offering SMA screening to newborn babies in England. The ISE is being brought forward to October 2026—it was originally planned for January 2027—so there will be more information to follow in October.

• 14 Apr 2026 · Cancer Treatment · Hansard source

  More

  Patients are 30 times more likely to wait two years for care in Scotland than in England. Labour has ended austerity and provided Scotland with the biggest funding increase since devolution. The question is: where has the money gone?

• 14 Apr 2026 · Cancer Treatment · Hansard source

  More

  We are backing cancer patients with a plan to end the postcode lottery that was baked in by the previous Tory Government due to chronic underfunding. We have already announced that more cancer specialists will be allocated to rural and coastal areas, increasing capacity where it is most needed. Over the past year, around 39,000 more people started their cancer treatment within 62 days, compared with the 12 months prior to the 2024 election.

• 14 Apr 2026 · Cancer Treatment · Hansard source

  More

  We are well aware that there are issues with the workforce across the NHS, which is why we are working on a new workforce plan that will be published in the spring—very soon.

• 14 Apr 2026 · Cancer Treatment · Hansard source

  More

  The national cancer plan is a key part of our work to build an NHS fit for the future, and it explains how we will make England a world leader in cancer outcomes. The right hon. Gentleman’s constituents will now be able to see a GP much sooner than they could before the 2024 election, which will ensure that they can get that earlier diagnosis, which is the only thing that will help them to survive and live longer.

• 14 Apr 2026 · Cancer Treatment · Hansard source

  More

  Unlike the Conservative party, we trust our GPs. This will be consultant-led advice and guidance, on which GPs will then decide.

• 14 Apr 2026 · Cancer Treatment · Hansard source

  More

  I commend my hon. Friend on her great work campaigning for her coastal community in East Thanet. The national cancer plan sets out how we will make sure that everyone has timely access to high-quality diagnostic and treatment services by increasing medical training places in rural and coastal areas. The national cancer plan will save 320,000 lives over the next decade and deliver the fastest improvement in cancer survival in UK history.

• 14 Apr 2026 · Cancer Treatment · Hansard source

  More

  Too many patients experience issues in accessing radiotherapy treatment, and I am sorry to hear about the experience of my hon. Friend’s constituent, John Kiely. We are determined to change that. After the previous Government’s chronic underfunding, this Government have invested £70 million of central funding on 28 new radiotherapy machines across the country to replace the older, less efficient machines. Providers have been allocated £15 billion in operational capital for local priorities and £5 billion to support a return to constitutional standards on waiting times. We expect local systems to use that capital to deliver further investment, and I encourage my hon. Friend to meet his local ICB to discuss this issue.

• 14 Apr 2026 · Topical Questions · Hansard source

  More

  I am very sorry to hear about Harley’s condition, and my thoughts are with him and his family. I am sure my hon. Friend understands that neither the Department nor NHS England can comment on the clinical appropriateness of suggested treatments for an individual. I understand that Harley and his family have already been in touch with the Department, and would suggest that my hon. Friend continues to raise this case with NHS England. We are committed to improving the lives of those living with rare diseases, including Harley’s condition of SCTS.

• 13 Apr 2026 · Young Cancer Patients: Experiences and Outcomes · Hansard source

  More

  I thank my hon. Friend the Member for Mansfield (Steve Yemm) for securing this very important debate, which, as we heard, is taking place during Teenage and Young Adult Cancer Awareness Month. I thank him for his very important work on the all-party parliamentary group on cancer in children and young people, as well as for his role as a parliamentary champion for the Teenage Cancer Trust. I am grateful to him for the invitation he has just made for me to visit a Teenage Cancer Trust unit, which I would be very pleased to accept. I pay tribute to some of the fantastic charities that he and I have both worked with: Teenage Cancer Trust, Young Lives vs Cancer and Children with Cancer UK, to name just a few. They supported us to write the national cancer plan. Now that the plan is published, they will play a vital role in its delivery. Cancer remains a leading cause of death for young people under the age of fourteen. I cannot begin to imagine what it must be like for those children and young people, who have their whole life ahead of them, to hear the words, “You have cancer,” not to mention those mums and dads who go through the nightmare of seeing their child suffer. It is true that 78% of children with cancer aged between eight and 15 said they were “very well looked after” by the NHS, but I will not be satisfied until that number reaches 100%. There are so many areas where we must do better, particularly when it comes to patient experience. My hon. Friend laid out clearly in his opening remarks what some of those areas are, so I will go through them one at a time. Thanks to my excellent predecessor, my hon. Friend the Member for West Lancashire (Ashley Dalton), we now have a plan that includes a dedicated chapter on children and young people setting out how the Government will address their unique needs. We will begin to shift the dial on detecting, diagnosing and treating cancers in young people, and we will continue to listen to young people and their families, through our patient experience panel, to ensure that lived experience sits at the heart of everything we do.

• 13 Apr 2026 · Young Cancer Patients: Experiences and Outcomes · Hansard source

  More

  I thank my hon. Friend for that important intervention. I will also commit to meeting him and the young people he mentions, perhaps in co-ordination with my visit to the Teenage Cancer Trust. I hope there will be plenty of opportunity to meet young people during that visit. It is a yes to both of those requests. We heard from the children and young people cancer taskforce how many parents have been forced to cut back on food and other expenses to pay for the travel to treatment. When a child is diagnosed with cancer, their family’s only focus should be on helping them to recover and getting them well, not on whether they can afford the petrol or the bus fare to get to their next appointment. That is why, through the plan, we are investing up to £10 million a year to support families with travel costs. This fund will make the world of difference to parents. It does not matter what someone earns; if their child needs treatment, we will help to get them there. We are also transforming the experience of care in hospital by making sure that every child and young person with cancer has access to high-quality, age-appropriate psychological support, which my hon. Friends the Members for Mansfield and for Redditch (Chris Bloore) both asked about. That support should be from diagnosis, through treatment and beyond; I will take on board the request of my hon. Friend the Member for Mansfield for that support to last up to two years post treatment. He spoke about the importance of early referrals to teenage and young adult multidisciplinary teams, with youth support co-ordinators on hand to help young people to navigate the huge journey they are going to have to go on, with the emotional impact of cancer alongside challenges around education, perhaps fertility and their long-term wellbeing. The Government are committed to diagnosing cancer in children and young people faster to ensure that they get the treatment and care they need as soon as possible. As my hon. Friend set out in his speech, this speed is of the utmost importance, so we will remove the barriers that stand in the way of timely diagnosis by making sure that young people’s needs are embedded into the design of neighbourhood health services. Just before recess, the Minister for Care announced the first 27 of 250 one-stop health shops that will be up and running next year, with 120 planned by the end of this Parliament. These offer a new model of care, as set out in our 10-year plan for health, with better access to specialist support and the safe roll-out of AI. Many colleagues—not least my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh)—have been pushing the Government for a long time to go further on research, which is why we are making research into improving outcomes for children, especially into kinder and more gentle treatments, a national research priority. The Department will take a more joined-up approach to research priorities using data, as my hon. Friend the Member for Mansfield urged us to do, so that efforts are focused where they can make the greatest difference. We will break down the barriers that prevent young people from accessing clinical trials, particularly those who do not often qualify for paediatric or adult trials, by requiring clinical justifications for age limits, while also strengthening data collection across the cancer pathway. In the next few months, the Department will establish a reformed national cancer board, once a co-chair has been appointed to oversee and monitor the implementation of our cancer plan. The board will include a dedicated lead for children and young people’s cancer, ensuring that this work is driven forward with clear accountability and focus. They will make sure that we are staying on track. I know that my hon. Friend the Member for Mansfield will play his part in that too. The Government believe that all children and young people, no matter their circumstances, deserve support to achieve the very best outcomes in life, but most importantly to live fulfilling and happy lives. Alongside our work on cancer, we are combating the drivers of ill health in children’s lives such as poor diet, damp homes, dirty air and a lack of opportunity. We have abolished the two-child benefit cap, taking half a million children out of destitution, shame and hunger. We have brought in free breakfast clubs and extended free school meals so that kids start school with hungry minds, not hungry bellies. We also introduced the soft drinks industry levy, a warm home discount scheme that reaches millions more, and a generational ban on smoking. Awaab’s law will cut pollution and clean up the air that our children breathe. This year, I am determined to do everything I can for children and young people with cancer. I have my foot on the accelerator, and I look forward to working closely with my hon. Friend in the months ahead on this work. Question put and agreed to .

• 26 Mar 2026 · Ehlers-Danlos Syndrome and Craniocervical Instability · Hansard source

  More

  I am happy to recommend that international best practice is looked at, and I will take that on board. I will also come to the suggestion from my hon. Friend the Member for Blaydon and Consett about the international best practice that we can learn from in Wales. Guidance matters too, and clinical guidelines and service specifications help reduce variation and improve quality. My hon. Friend the Member for Blaydon and Consett asked about NICE guidance. Where NICE guidance exists, the NHS is expected to take it into account, and where it does not, we should consider what other guidance can support clinicians and patients in the interim. I commit to asking the NICE prioritisation board, chaired by its chief medical officer, if it will look at the Wales pathways that she suggested when it considers updating NICE guidance. My hon. Friend also asked about multidisciplinary teams. NHS England, along with the neurosurgery and spinal surgery clinical reference group, has not currently identified a need for an MDT. NHS England has established clinical networks for spinal surgery and neurosurgery, and we expect those networks to work closely to ensure that both cranial and spinal pathways are optimised. I was also asked about a pathway by my hon. Friend the Member for Truro and Falmouth. There is currently no separate national diagnostic or treatment pathway for CCI because it is not recognised as a distinct NHS diagnosis, and there is no agreed national definition, validated imaging criteria or robust evidence base to support creating one. However, the Department recognises the concerns that patients have raised, and we are working with NHS England, clinical networks and patients’ organisations to improve pathway consistency by strengthening the existing framework, so we will look further into that.

• 26 Mar 2026 · Ehlers-Danlos Syndrome and Craniocervical Instability · Hansard source

  More

  I did touch on research, but I did not specifically mention universities. I am pleased that the hon. Member got in another plug for the wonderful Queen’s University Belfast—he did that when we were in this Chamber the other day—and I will take his point on board. I thank him for that. In closing, I return to the people at the heart of this debate: those living with EDS and CCI. Connor, Jo, Rebekah, Carley, Hannah, Stevie and Natasha have been named by their MPs today. They and their testimonies, as we have heard, are just examples of the many more people across the UK and Northern Ireland suffering from these terrible conditions. They are not asking for miracles; they are asking for clarity, consistency, safe care and to be treated with respect. They are asking for a system that joins up around them, rather than leaving them to piece it together alone. That is a reasonable ask, and one that we should meet. Again, I thank my hon. Friend the Member for Cannock Chase for securing this very important debate. I look forward to working with NHS partners, clinicians and patient groups to ensure that people living with these complex conditions receive the timely, safe and compassionate support and care that they deserve.

• 26 Mar 2026 · Ehlers-Danlos Syndrome and Craniocervical Instability · Hansard source

  More

  I will commit to looking into that for my hon. Friend. Obviously, aftercare for surgery abroad is tricky—not for conditions such as this, but often for beauty related purposes—but I will take that on board and take it back to the Department.

• 26 Mar 2026 · Ehlers-Danlos Syndrome and Craniocervical Instability · Hansard source

  More

  It is a pleasure to serve under your chairmanship, Ms Furniss. I thank my hon. Friend the Member for Cannock Chase (Josh Newbury) for securing this very important debate and for his excellent opening speech, in which he took great care to set the scene for us. I appreciate that. My hon. Friend has been instrumental in bringing national attention to the challenges faced by people living with Ehlers-Danlos syndrome and craniocervical instability. Last year my predecessor in my role, my hon. Friend the Member for West Lancashire (Ashley Dalton), met him and his constituent, Connor Edwards, who has suffered greatly, as we have heard, from the impact of these devastating conditions. Connor has faced immense physical and emotional hardship as he has tried to navigate symptoms linked to EDS and CCI, enduring pain, uncertainty and long waits for answers, as we have heard. His experience reflects what too many patients and families have told us: that the system can feel fragmented, that they are often left to join up their own care, and that the lack of clear pathways can add to an already overwhelming burden. I want to assure Connor and others in his position that their voices have been heard.

• 26 Mar 2026 · Ehlers-Danlos Syndrome and Craniocervical Instability · Hansard source

  More

  Yes, I would imagine that if the Department looks at it and it is deemed necessary, that is what will happen. I am sure that my hon. Friend can follow up on that as time progresses. I will cover the last couple of questions from hon. Members. My hon. Friend the Member for Truro and Falmouth, the hon. Member for Ashfield and my hon. Friend the Member for Stratford and Bow made points about access to care and ensuring that people do not fall through the cracks. EDS and CCI often require input from rheumatology, neurology, pain services, physiotherapy, genetics and primary care, and the 10-year health plan’s emphasis on integrated multidisciplinary care models will help to join up those pathways for the first time. That will reduce repeat referrals and conflicting advice, and patients feeling that they must be the ones to join up the system. We will hopefully see progress on that through the 10-year plan. The hon. Member for Ashfield also asked about wheelchair services. In England, they are commissioned locally by ICBs and eligibility is determined by functional need, lifestyle and clinical assessment, not by whether a patient has a specific condition such as EDS or CCI. NHS England has developed a model service specification for wheelchair and posture services that sets clear expectations for timely assessment, appropriate prescribing and user-centred provision. That specification enables commissioners to organise consistent, high-quality services that meet individual mobility needs, including those arising from complex conditions such as EDS and CCI, so I was keen to give the hon. Member an answer to that particular question. The 10-year health plan sets a clear direction for improving outcomes for people with EDS and those experiencing symptoms associated with CCI. The plan prioritises earlier diagnosis, better co-ordinated care and stronger multidisciplinary working across primary, community and specialist services, which are key issues consistently raised by patients and families. It promotes integrated, personalised support closer to home, reducing the burden of navigating multiple services. The plan also expands the use of digital tools, remote monitoring and personalised care planning to help people manage complex, fluctuating symptoms more effectively. Importantly, it commits to strengthening research, clinical education and system-wide awareness of overlapping, multi-system conditions, helping to ensure that people with EDS and CCI receive more consistent, compassionate and joined-up care. Let me clear about what I can commit to as the Minister today. I will ensure that the concerns that have been raised are shared with NHS England to help identify where guidance, pathways, referral routes or clinical advice could be clearer and where good practice is already emerging internationally—as well as in Wales—that could be spread more consistently. Meaningful engagement with those directly affected must sit at the heart of our approach. Departmental officials are already in discussions with patient groups, and that ongoing engagement will be invaluable in shaping our understanding and ensuring that future policy is grounded in the reality of patients’ lives. We will be asking the NIHR to consider how best to encourage further quality research in this area. It is already expanding its work on conditions with overlapping symptom profiles, including myalgic encephalomyelitis and chronic fatigue syndrome, and post-viral syndromes, and we want to ensure that future research programmes recognise the clear need for better evidence on diagnosis, management and outcomes for people with EDS and suspected CCI. I commit to continuing to press for a culture that is compassionate and evidence-based—one that listens to patients, avoids dismissal and false certainty, and supports shared decision-making.

• 26 Mar 2026 · Ehlers-Danlos Syndrome and Craniocervical Instability · Hansard source

  More

  I thank the hon. Gentleman on behalf of his constituent, Natasha, and I will make sure that I include her name later when I come on to name everyone referred to during the debate. I also thank him for managing to juggle and spin all the plates that we have to deal with as Members by making time to come along to this debate. I also thank all the other hon. Members who managed to make it to this very important debate. We heard contributions from my hon. Friends the Members for Hitchin (Alistair Strathern), for Glasgow West (Patricia Ferguson), for West Dunbartonshire (Douglas McAllister), and for Stratford and Bow (Uma Kumaran); from my right hon. Friend the Member for Hayes and Harlington (John McDonnell); from my hon. Friend the Member for Truro and Falmouth (Jayne Kirkham); from the hon. Members for Strangford (Jim Shannon) and for Ashfield (Lee Anderson); from my hon. Friend the Member for Blaydon and Consett (Liz Twist); from the hon. Member for Tiverton and Minehead (Rachel Gilmour); from my hon. Friend the Member for Bury St Edmunds and Stowmarket (Peter Prinsley); from the hon. Members for Winchester (Dr Chambers) and for Epping Forest (Dr Hudson); and from the spokesperson for the Conservatives, the hon. Member for Fylde (Mr Snowden). I also thank the hon. Member for Fylde for sharing his learnings from the experience of his sister, Kimberley, on her journey in treatment for epilepsy. As he explained, epilepsy is a well-known condition, especially in comparison with the conditions that we are discussing today. That was a very strong point, which I thank him for making. I will not repeat the detailed clinical descriptions of Ehlers-Danlos syndrome and craniocervical instability that other hon. Members have already set out very clearly, but I do want to recognise the real and often profound challenges that people living with these conditions, and their families, face every day. I want those individuals to know that I hear them, and that I recognise the challenges they face and the uncertainty and distress that many describe. Their experiences will shape the Department’s ongoing work as we consider how services can better meet the needs of people living with these complex conditions. NHS England continues to strengthen clinically led pathways for people with hypermobility-related disorders, with an emphasis on non-surgical management, co-ordinated physiotherapy, and pain management and rehabilitation, as is consistent with the best available evidence. In response to the question from the hon. Member for Strangford about the number of people affected by these conditions, the Getting It Right First Time programme is supporting more consistent assessment and management of complex joint and spine conditions, and assessment of the number of people affected, helping to reduce the unwarranted variation in treatment that particularly affects people with EDS. The programme has a strong emphasis on robust, evidence-based and personalised pathways. Through RightCare, integrated care systems are supported to commission evidence-based pathways for long-term and complex conditions, including improved access to community-based musculoskeletal care, which many people with EDS rely upon. My hon. Friend the Member for Blaydon and Consett mentioned some numbers in her contribution, quoting a ratio of one in 250 and saying that between 1% and 4% of the population are affected. I would imagine that those are the ballpark figures, but the Getting It Right First Time and RightCare programmes, which I have just mentioned, will look into that in more detail. How can we facilitate better care and support? We need better clinical education, clearer referral routes and a stronger emphasis on shared decision making. We also need to recognise the burden of chronic pain and fatigue that comes with these conditions, and ensure that people can access appropriate services, even when a definitive single diagnosis may still be evolving. Where the evidence is established, the NHS should provide timely, appropriate care. Where evidence is uncertain, we have a responsibility to be transparent about what is known, what is not known and what options are supported by clinical consensus. Patient safety must always be paramount, and decisions about invasive treatments must be made within appropriate specialist teams, with robust clinical governance, multidisciplinary review and clear plans to follow up. EDS illustrates why integrated care matters. Pathways must connect primary care, community therapy services and specialist support so that patients do not have to tell their story over and over again, or navigate multiple disconnected services. Stronger evidence is also imperative. The Government support health research through the National Institute for Health and Care Research, and we want to see well-designed studies that can inform future guidance and reduce unwarranted variation.

• 24 Mar 2026 · Sudden Unexplained Death in Childhood · Hansard source

  More

  I take on board what the hon. Lady says. When I write to her on the point about responses to recommendations, I will elaborate further on that point, having made sure that I have understood it correctly.

• 24 Mar 2026 · Sudden Unexplained Death in Childhood · Hansard source

  More

  Yes. I thank the hon. Member for his very moving speech; he often moves me to tears in moments such as this. I will take that away, and ask my officials to look at the work of Queen’s University Belfast, because he makes a very important point. The shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson), made a couple of points. I will write to her on the Government’s responses to recommendations, because it is a valid point and one that we should be aware of in future. On the point about ICBs making services more effective by cutting duplication and making sure we have the right people in the right places to deliver quality services, that is something I will also be paying particular attention to, as the Minister with responsibility for children’s health.

• 24 Mar 2026 · Sudden Unexplained Death in Childhood · Hansard source

  More

  I think I may have mentioned some Government-funded research, but I will commit to write to the hon. Gentleman on that point, rather than try to guess what I may have said. In closing, I again thank my hon. Friend the Member for Rossendale and Darwen for bringing forward this debate, and all hon. Members for their heartbreaking speeches. Those of us here today who have had the privilege of taking part in this debate will never forget them and the names of the children either: Frankie, Miranda, Jack, Louis and Harry—as well as all the other precious children who we have lost to SUDC. The names, families and circumstances mentioned today are all in Hansard now forever. I want to thank all the families in the Public Gallery for being with us today and for their campaigning for change, research and better support. A number of Members here today recognise that drive because it is what drove us here ourselves. I take on board the plea from the hon. Member for Spelthorne (Lincoln Jopp) to ensure that we see progress and do not all find ourselves back here in a few years’ time having the same debate. We will continue to work with clinicians, researchers, charities and—above all else—families to deepen our understanding, strengthen the support available, and ensure that every child’s death is fully examined and that their life is never forgotten.

• 24 Mar 2026 · Sudden Unexplained Death in Childhood · Hansard source

  More

  It is a pleasure to serve under your chairmanship, Sir John. I thank my hon. Friend the Member for Rossendale and Darwen (Andy MacNae) for securing a debate on such an important issue. I am grateful to him for opening the debate during SUDC Awareness Month, a time dedicated to remembering children who have died suddenly and without explanation. I also thank my hon. Friend for sharing Frankie’s story; it was profoundly moving to hear about it, as it was to hear all the contributions this morning. I want to acknowledge the courage of Frankie’s family in turning such devastating loss into a call for understanding and change. Frankie was clearly a much-loved little boy, as are all the children who are lost to SUDC, and no family should have to live with unanswered questions about why their child died. I am grateful to Frankie’s grandfather and SUDC UK for their determination in making sure that unexplained never means unexamined. I recognise the importance of the leadership, co-ordination and clarity that they are asking for. It is important to me that we strengthen our understanding of SUDC and ensure that families can access the right support when they need it. This Government set out an ambitious commitment to raise the healthiest generation of children ever. To achieve that, we must ensure that families receive the best support and advice on all matters relating to child health, including SUDC. I thank all hon. Members for their powerful and moving speeches and interventions today. I turn to some of the specific issues raised. I recognise the calls from a number of Members for a national plan. That is why we are strengthening pathology services, ensuring high-quality bereavement support and a growing research base. As that works progresses, we will continue listening to families, clinicians and researchers about where further improvements are needed. My hon. Friend the Member for Doncaster Central (Sally Jameson) asked me about bereavement leave, and made a very strong case. I will commit to raising that with Department for Business and Trade Ministers as a priority. I will also raise the issue of police and paramedic training, which my hon. Friend the Member for Altrincham and Sale West (Mr Rand) raised, with the relevant Departments and Ministers. Both my hon. Friends raised very important issues. My hon. Friend the Member for Warrington South (Sarah Hall) asked about the implementation of the recommendations in the paediatric and perinatal pathology workforce report. I will write to her on that, and on the four points she called for in particular. I thank my hon. Friend the Member for Rossendale and Darwen for highlighting that information on SUDC was taken down from the NHS website. Parents who have lost a child to SUDC should be able to access the advice and support that they need. I have already asked my officials to investigate that and explore opportunities to include signposting on the NHS website. No family should ever have to experience the loss of a child, as so many of us in this Chamber today have. It is vital all of us have access to compassionate and timely support when the worst happens. The child death review process ensures that every child’s death is understood sensitively and thoroughly, and is vital in helping families to understand what happened to their child. While bereavement support is commissioned locally to reflect the needs of each community, there is clear national best practice that sets out that every bereaved family should have a key worker to guide them through a time of inconceivable loss and heartbreak. That key worker helps to provide clarity, information and kindness, and helps families to access further sources of support where needed. We also encourage anyone seeking help to contact their GP, who can also guide them to appropriate services. I also want to thank some of the wonderful organisations and charities across the country, such as SUDC UK, the Lullaby Trust, Cruse Bereavement Support and the Good Grief Trust, which provide exceptional support to families experiencing this devastating loss. Alongside that, the National Bereavement Alliance has published updated voluntary service standards to support continuous improvement in the quality of care. Putting the needs of children and their families first is at the heart of everything I will do in my role as a Minister. We will continue working with partners to ensure that bereaved families receive the compassion and support they deserve. As we have heard today in detail, pathology waiting times can add to the distress experienced by families at a critical time when they need answers quickly. As was highlighted by the hon. Member for Mid Sussex (Alison Bennett), who speaks for the Liberal Democrats, there is a nationwide shortage of paediatric pathologists in England and Wales, which can affect the time taken to complete pathology testing following a coronial post-mortem. To address that, NHS England has launched a national programme to strengthen perinatal and paediatric pathology services. The Government have made more than £2 million-worth of additional funding available to increase post-mortem capacity. That has increased training posts and the number of trainee doctors and new pathologists. Alongside that, genomic testing for SUDC is available through the NHS genomic medicine service. Decisions about whether genomic testing is appropriate are made after the post-mortem and through careful discussions with specialist multidisciplinary teams. NHS England closely monitors how genomic testing is delivered across the country, so that it can spot where services differ and work with local teams to improve services. That helps to ensure families can benefit from high-quality, consistent services where they live. Taken together, these steps will help to ensure that families receive timely, high-quality investigations at moments of profound difficulty, while supporting the workforce who deliver this critical service. As hon. Members have said, SUDC remains an under-researched area, and I agree that we must do more to deepen our understanding. The Government remain open to funding high-quality research into SUDC through the National Institute for Health and Care Research, and we welcome applications on any aspect of child health, including SUDC. For example, I thank my hon. Friend the Member for Rossendale and Darwen for raising the great work of Bristol University in hosting the national child mortality database and child mortality analysis unit. The Government’s support for the national child mortality database has already made a meaningful difference by bringing together national-level data on all child deaths in England and allowing a far greater understanding of deaths in children over the age of one. I am encouraged to see that, building on that foundation, the University of Bristol has secured funding from SUDC UK for the Pioneer SUDC study. This will help to shape future research questions and contribute to deeper learning in this under-explored area. As this growing body of evidence develops, it will allow experts to identify where research can have the greatest impact and where gaps remain, including in areas such as febrile seizures. I thank my hon. Friend for raising that area today, because it is definitely one we need to look at.

• 24 Mar 2026 · Endometriosis Services · Hansard source

  More

  Yes—I or my colleague in the Department will undertake to look at that and ensure the hon. Lady receives a response. In response to questions on data and research raised by my hon. Friend the Member for Hampstead and Highgate (Tulip Siddiq), and the hon. Members for Strangford (Jim Shannon) and for Bath (Wera Hobhouse), the Department, through the National Institute for Health and Care Research, has commissioned several studies focused on endometriosis diagnosis, treatment and patient experience. At present, the NIHR is funding six active research awards, totalling an investment of approximately £7.8 million. That includes a new £2.3 million award on the effectiveness of pain management for endometriosis, starting this month. In response to the hon. Member for Strangford asking the Department to engage with health Ministers in the Northern Ireland Executive to discuss any learnings, best practice and areas to improve, I commit to do that. That is a great suggestion. The hon. Member for Bath asked me about the Women and Equalities Committee inquiry into reproductive health conditions. I am grateful for the work that Committee is doing and welcome its report on that important topic. The Department will be issuing an official response to the report’s recommendations in due course. Research has already led to new treatments being made available, including NICE approval of two pills to treat endometriosis, relugolix and linzagolix—oh, to have the skill of a doctor in pronouncing these complicated drug names! Those drugs are estimated to help around 1,000 women with severe endometriosis for whom other treatment options have not been effective. No one should have to put up with chronic pain, which is one of the most common symptoms of endometriosis. The renewed women’s health strategy is under development, so I cannot say exactly what will be included, but the published strategy will set out the actions we are taking to improve women’s experiences, including around pain. As part of our engagement informing the renewal of that strategy, we held a roundtable on women’s experiences of pain, chaired by Baroness Merron and attended by women with lived experience and by expert organisations. That roundtable is informing our work to renew the strategy. Better care also depends on better understanding. Improving public and healthcare professionals’ awareness of endometriosis will reduce the stigma, of which a number of Members spoke, and will ensure that symptoms are recognised rather than normalised or dismissed. In response to the concern of my hon. Friend the Member for Hampstead and Highgate about DWP training for assessors, I commit to write to the DWP to make that very point. In response to the hon. Member for Chichester (Jess Brown-Fuller) and the Liberal Democrat spokesperson, the hon. Member for North Shropshire (Helen Morgan), the General Medical Council has strengthened women’s health representation in training. Since last year it has required UK medical graduates to pass the medical licensing assessment, encouraging a better understanding of common women’s health problems. That assessment includes topics on women’s health, including endometriosis. Women’s health is also built into the Royal College of General Practitioners’ curriculum for trainee GPs, which brings together educational resources and clinical guidance to support primary care teams. Clinical guidance has been strengthened, too: NICE updated its endometriosis guidelines in 2024 to support more consistent decision making and faster routes to specialist input. NICE is working with the NHS to ensure the adoption of this best practice for endometriosis care, including access to approved medicines. Research indicates that women’s experiences of healthcare are not uniform, as we have heard, and particularly that outcomes can vary sharply between different communities. Ethnically diverse women with endometriosis can encounter additional hurdles in getting a diagnosis and appropriate support. We will not accept those disparities as inevitable. Our ambition is for a fairer Britain, where people live well for longer and spend less time in ill health, and where women, whatever their background, can rely on high-quality care.

• 24 Mar 2026 · Endometriosis Services · Hansard source

  More

  That was an excellent intervention, I have to say; I am glad that we will all be out of here in time to go and enjoy that. For the ladies and gentlemen in the Gallery, do not worry: it is free entry and no invite is needed. I thank my hon. Friend the Member for Erith and Thamesmead (Ms Oppong-Asare) for all she does on women’s health. She has led the way, more than most in Parliament, on the issue in her time here. That is recognised, and I thank her for it. We are hopefully shifting the centre of gravity of care from hospitals to communities, with neighbourhood services designed around local need. Earlier this month, we published a neighbourhood health framework, setting out three reform agendas for ICBs, local authorities and civil society to deliver the aims of neighbourhood health. We have done this to improve services for people who need routine healthcare; to improve proactive care, including maintaining and developing access to women’s health services; and to deliver better alternatives to hospital care.

• 24 Mar 2026 · Endometriosis Services · Hansard source

  More

  I am grateful to the hon. Gentleman for bringing the details of Ami’s case to us. Waiting 22 years for a diagnosis is shocking, and I suppose it would have been very difficult to have continuity of care over such a long time, but I take on board the point that he makes. When we—myself included—go to the GP, we often see a different person every time. As I said, this is not my brief, so I will feed his request for a meeting back to the Minister for Secondary Care. I cannot promise on her behalf, but we have heard his request. The framework I was just outlining provides clarity and consistency, supporting joined-up partnership between ICBs and local authorities, working together to develop locally led neighbourhood health plans. This will hopefully address some of the concerns raised by the hon. Member for Yeovil (Adam Dance) about continuity of care. Since coming into office, this Government have delivered over 5 million extra appointments in our first year; reduced the numbers on gynaecological waiting lists by over 24,000 women; and given women easier access to the morning-after pill, free of charge. A lot done; a lot more to do. We have made strong progress in turning the commitments in the last Government’s women’s health strategy, which the hon. Member for Hinckley and Bosworth highlighted, into tangible action. Our renewed strategy will set out how this Government are taking further steps to improve women’s health as we deliver the 10-year health plan. It will address gaps from the 2022 strategy, and go further to create a system that listens to women, tackles health inequalities and makes progress on conditions such as endometriosis. Renewing the strategy will help identify and remove enduring barriers to high-quality care, such as long waits for diagnosis, and will ensure professionals listen and respond to women’s needs. I thank my hon. Friend the Member for Ipswich for bringing forward this important debate, and all hon. Members for sharing so many of their constituents’ stories. I give special thanks to Monica and all the women who are in the Public Gallery to bear witness and push us to do more. We have heard them, and I commit to doing what I can to ensure that their efforts have not been in vain.